Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.
Shares of Spero catapulted 228% as intraday trading volume soared to over 166.9 million from a daily average of about 131,000.
Signing Day Sports (SGN) said Wednesday that it has signed a definitive business combination agreement to buy One Blockchain, the operating affiliate company of data hosting firm BlockchAIn Digital Infrastructure.
Shares of Signing Day soared 178%, with intraday trading volume at over 153.2 million compared with a daily average of roughly 1.7 million.
Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.
Shares surged 148% as intraday trading volume advanced to more than 567.3 million from a daily average of about 739,000.
Price: 2.24, Change: +1.56, Percent Change: +228.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。